Home › Gastrointestinal Stromal Tumors › Ohio › Cleveland
Gastrointestinal Stromal Tumors clinical trials in Cleveland, OH
4 studies for Gastrointestinal Stromal Tumors are looking for participants at sites in and around Cleveland (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RecruitingPhase 2
- Cleveland Clinic - Oncology Department, Cleveland
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
RecruitingPhase 2
- Cleveland Clinic, Cleveland
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
RecruitingPhase 1/2
- Cleveland Clinic Taussig Cancer Center, Cleveland
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RecruitingPhase 1
- Case Comprehensive Cancer Center, Cleveland
Gastrointestinal Stromal Tumors trials in other cities
- Miami, FL8 studies
- Boston, MA7 studies
- New York City, NY7 studies
- Philadelphia, PA6 studies
- Houston, TX6 studies
- Nashville, TN5 studies
- San Diego, CA5 studies
- Portland, OR5 studies
- Omaha, NE5 studies
- Dallas, TX4 studies
- Durham, NC4 studies
- Chicago, IL4 studies
Other studies in Cleveland
- Non-Small Cell Lung Cancer43 studies
- Cancer (all types)36 studies
- Breast Cancer35 studies
- Prostate Cancer34 studies
- Heart Failure33 studies
- Ovarian Cancer30 studies
- Metastatic Cancer30 studies
- Lung Cancer26 studies
- Colorectal Cancer24 studies
- Cardiovascular Disease22 studies
- Endometrial Cancer20 studies
- Acute Myeloid Leukemia20 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.